Prevalence of cardiovascular and renal comorbidities among patients with type 2 diabetes routinely treated in the primary care setting in Greece: An epidemiological study (the RECARDIA study).

AIMS

This study aimed to generate real-world data on the prevalence of cardiovascular disease (CVD), including atherosclerotic CVD (ASCVD) and heart failure (HF), as well as chronic kidney disease (CKD) in patients with type 2 diabetes mellitus (T2DM) routinely treated in Greece.

METHODS

This was a non-interventional, epidemiological, multicentre, cross-sectional and retrospective chart review study of T2DM patients attending a routine clinical visit at 198 outpatient primary care settings across Greece from November 2020 to February 2022.

RESULTS

Among 2000 enrolled T2DM outpatients, the prevalence of ASCVD was 20.40 % (95 % confidence interval [CI]: 18.67 %-22.25 %), of HF 8.03 % (95 % CI: 6.67 %-9.63 %), and of CKD 49.55 % (95 % CI: 47.36 %-51.74 %). Hypertension was correlated with increased risk of ASCVD, HF or CKD, dyslipidaemia with ASCVD and CKD, obesity solely with HF, and smoking with ASCVD. Patients over 65 years were at higher risk of ASCVD, HF or CKD, whereas those with T2DM for ≥10 years had a higher risk of ASCVD or HF. Finally, males were more likely to have ASCVD CONCLUSIONS: The present study confirms the high prevalence of CVD and CKD among Greek T2DM patients managed in primary care, that potentially qualify for new antidiabetic treatments with cardiovascular or renal benefits.